CRP genetic variants are associated with mortality and depressive symptoms in chronic heart failure patients

S Kittel-Schneider1, M Kaspar2, D Berliner3

  • 1Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital of Frankfurt, Frankfurt, Germany; Comprehensive Heart Failure Center, University Hospital of Würzburg, Würzburg, Germany.

Insights

Certain genetic variations in the C-reactive protein (CRP) gene are linked to higher mortality risk and increased depressive symptoms in heart failure (HF) patients. These findings suggest inflammation may connect HF prognosis and depression.

Area of Science:

  • Cardiology
  • Genetics
  • Psychiatry

Background:

  • Heart failure (HF) is a complex condition influenced by genetic and other factors.
  • Inflammatory mechanisms and depressive symptoms are increasingly recognized in HF pathogenesis and outcomes.
  • Depression is prevalent in HF patients and acts as a risk factor for cardiovascular disease.

Purpose of the Study:

  • To investigate the association between genetic variants of CRP and IL-6 and mortality in HF patients.
  • To explore the relationship between CRP and IL-6 genetic variants, CRP/IL-6 blood levels, and depressive symptoms.

Main Methods:

  • Analyzed blood levels of C-reactive protein (CRP) and Interleukin-6 (IL-6) in 936 heart failure patients.
  • Examined single nucleotide polymorphisms (SNPs) in the CRP and IL6 genes for their impact on mortality.
  • Assessed depressive symptoms using the PHQ-9 scale.

Main Results:

  • Recessive genotypes of two CRP gene SNPs (rs1800947 and rs11265263) were associated with significantly higher mortality risk.
  • These CRP variants correlated with elevated CRP blood levels and increased depressive symptoms.
  • No significant association was found between IL-6 gene variants and mortality.

Conclusions:

  • Less common CRP genetic variants may be linked to increased mortality, depressive symptoms, and CRP levels in HF patients.
  • The inflammatory system might serve as a link between poor HF prognosis and depressive symptoms.
  • Further research into CRP genetics could elucidate pathways connecting inflammation, HF outcomes, and depression.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360